Merck's Full Court Press On Oncology

16:18 EDT 14 Jun 2019 | Forbes

Earlier this week, Merck entered into an agreement to acquire Tilos Therapeutics for up to $773 million. Such acquisitions demonstrate how heavily invested Merck is in immuno-oncology, an area in which it is currently well-positioned with the PD-1 inhibitor Keytruda.

Original Article: Merck's Full Court Press On Oncology


More From BioPortfolio on "Merck's Full Court Press On Oncology"

Quick Search


Relevant Topics

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.